This inventor holds 2 USPTO granted patents. Top assignee: Corvas International, Inc.. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: Innovations of Jonathan Zhanqi Ho in Thrombin Inhibition
Introduction
Jonathan Zhanqi Ho is a notable inventor based in Beijing, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of thrombin inhibitors. With a total of 2 patents, his work focuses on creating compounds that can effectively treat abnormal thrombosis in mammals.
Latest Patents
Ho's latest patents include innovative compounds designed to inhibit thrombin. The first patent, titled "Thrombin inhibitors having a lactam at P3," describes compounds featuring a lactam ring at P3 and a six-membered heterocyclic ring at P1. These compounds demonstrate potent biological activity as thrombin inhibitors and include pharmaceutically acceptable salts and compositions for therapeutic use. The second patent, "Non-covalent thrombin inhibitors," presents compounds with a pyrazinone or pyridinone ring at P3, also exhibiting strong inhibitory effects on thrombin. Both patents emphasize the potential of these compounds in treating disease states characterized by abnormal thrombosis.
Career Highlights
Jonathan Zhanqi Ho is currently associated with Corvas International, Inc., where he continues to advance his research in thrombin inhibition. His work is pivotal in developing new therapeutic agents that can significantly impact patient care.
Collaborations
Ho collaborates with esteemed colleagues such as Joseph Edward Semple and Daniel Vanna Siev, contributing to a dynamic research environment that fosters innovation.
Conclusion
Jonathan Zhanqi Ho's contributions to thrombin inhibition represent a significant advancement in medicinal chemistry. His innovative patents and collaborative efforts are paving the way for new therapeutic solutions in the treatment of thrombosis-related conditions.